Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunecompetent rats

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4530-4536

  Sjögren, Hans Olov ^a,c   Isaksson, M ^a   Willner, David ^b   Hellström, Ingegerd ^b   Hellström, Karl Erik ^b   Trail, Pamela A ^b  

^a LUND UNIVERSITY   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

^c Department of Marcus   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MONOCLONAL ANTIBODY BR 96; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; COLON CARCINOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTOXINS; LIVER NEOPLASMS; MICE; MICE, NUDE; RATS; RATS, INBRED BN; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 1842369073     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Riethmüller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
2. Pietersz, G. A., Krauer, K., and McKenzie, I. F. The use of monoclonal antibody immunoconjugates in cancer therapy. Adv. Exp. Med. Biol., 353: 169-179, 1994.
3. Hellström, I., Hellström, K. E., Siegall, C. B., and Trail, P. A. Immunoconjugates and immunotoxins for therapy of carcinomas. In: J. T. August, M. W. Anders, F. Murad, and J. T. Coyle (eds.), Advances in Pharmacology, Vol. 33, Ed. 1, pp. 349-388. San Diego: Academic Press, 1995.
4. Trail, P. A., Willner, D., and Hellström, K. E. Site-directed delivery of anthracyclines for cancer therapy. Drug Dev. Res., 34: 196-209, 1995.
5. 131I] anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
6. Press, O. W., Eary, J. F., Appelhaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D. P., B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1268, 1993.
7. Jain, R. Barriers to drug delivery in solid tumors. Sci. Am., 271: 58-65, 1994.
8. y-related cell surface antigen. Cancer Res., 50: 2183-2190, 1990.
9. y specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am. J. Pathol., 142: 607-622, 1993.
10. Fell, H. P., Yarnold, S., Hellström, I., Hellström, K. E., and Folger, K. R. Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting. Proc. Natl. Acad. Sci. USA, 86: 8507-8511, 1989.
11. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S. J., Casazza, A. M., Firestone, R. A., Hellström, I., and Hellström, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (Washington DC), 261: 212-215, 1993.
12. Willner, D., Trail, P. A., Hofstead, S. J., King, H. D., Lasch, S. J., Braslawsky, G. R., Greenfield, R. S., Kaneko, T., and Firestone, R. A. (6-Maleimidocaproyl)hydrazone of doxorubicin: a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconj. Chem., 4: 521-527, 1993.
13. Li, Y., Newby, S. A., Johnston, J. V., Hellström, K. E., and Chen, L. Protective immunity induced by B7/CD28-costimulated mice γ δ T cells to the EL-4 lymphoma in allogeneic athymic mice. J. Immunol., 155, 5705-5710, 1995.
14. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Greenfield, R. S., King, D., Zoeckler, M. E., and Braslawsky, G. R. Antigen specific activity of carcinoma reactive BR64-adriamycin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res., 52: 5693-5700, 1992.
15. Trail, P. A., Willner, D., Knipe, J., Henderson, A. J., Lasch, S. J., Casazza, A. M., Zoeckler, M. E., TrailSmith, M. D., Doyle, T. W., King, H. D., Braslawsky, G. R., Greenfield, R. S., Hofstead, S. J., Firestone, R. A., Mosure, K. W., Kadow, K. F., Yang, M. B., Hellström, K. E., and Hellström, I. Effect of linker variation on the stability, potency, and efficacy of carcinoma reactive BR64-doxorubicin immunoconjugates. Cancer Res., 57: 100-105 1997.
16. Freireich, E. J., Gehan, E. A., Rail, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep., 50: 219-243, 1966.
17. Tepper, M. A., and Kelley, S. L. Deoxyspergualin for immune suppression. In: E. S. Kimball (ed.), Immunopharmaceuticals. Boca Raton, FL: CRC Press, 1995.
18. Pai, L. H., FitzGerald, D. J., Tepper, M., Schacter, B., Spitalny, G., and Pastan, I. Inhibition of the antibody response to Pseudomonas exotoxin and immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res., 50: 7750-7753, 1990.
19. Trail, P. A., Slichenmyer, W. J., Birkhofer, M. J., Warner, G., Knipe, J., Willner, D., Firestone, R. A., Sikkema, D., Onetto, N., Canetta, R., Saleh, M. N., Murray, J. L., Gilewski, T. A., Bookman, M. A., Hellström, I., and Hellström, K. E. BR96-doxorubicin immunoconjugate for treatment of patients with carcinoma. Proc. Am. Assoc. Cancer Res., 37: 626, 1996.